Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
about
Non-muscle myosin II in disease: mechanisms and therapeutic opportunitiesImmune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesHuman airway musculature on a chip: an in vitro model of allergic asthmatic bronchoconstriction and bronchodilation.Genetic interference with peroxisome proliferator-activated receptor γ in smooth muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-dependent mechanism.Incarvine C suppresses proliferation and vasculogenic mimicry of hepatocellular carcinoma cells via targeting ROCK inhibition.Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays.Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammation associated with various neurological diseases including autism spectrum disorder.A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion.ROCK Inhibition Promotes Attachment, Proliferation, and Wound Closure in Human Embryonic Stem Cell-Derived Retinal Pigmented EpitheliumIn silico prediction of ROCK II inhibitors by different classification approaches.L-F001, a Multifunction ROCK Inhibitor Prevents 6-OHDA Induced Cell Death Through Activating Akt/GSK-3beta and Nrf2/HO-1 Signaling Pathway in PC12 Cells and Attenuates MPTP-Induced Dopamine Neuron Toxicity in Mice.Partial contribution of Rho-kinase inhibition to the bioactivity of Ganoderma lingzhi and its isolated compounds: insights on discovery of natural Rho-kinase inhibitors.Exopolysaccharides from Lactobacillus plantarum NCU116 induce c-Jun dependent Fas/Fasl-mediated apoptosis via TLR2 in mouse intestinal epithelial cancer cells.Multi-Objective Optimization of Benzamide Derivatives as Rho Kinase Inhibitors.Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.Rho-kinase inhibitors from adlay seeds.The cyclohexene derivative MC-3129 exhibits antileukemic activity via RhoA/ROCK1/PTEN/PI3K/Akt pathway-mediated mitochondrial translocation of cofilin.
P2860
Q26778962-3C16744D-81F5-4B35-8576-83AA298EDFD2Q28081001-2E8E33E3-D5C2-4036-B50E-109816B8F2FAQ34205274-0C43EC1C-0E4A-4AA5-BE00-D5198DC50F8EQ34892807-CF7BB7AE-3088-40F8-89EA-33F1850C0C61Q35824952-DCC8C2DD-79FB-483C-8728-41852317A315Q36280727-CCBF22E9-DC80-4169-B250-EAF0B53E568FQ38260925-5FB7DF35-2CB3-4BD4-88E0-5FA4BF5681A9Q38584194-4F8FBB1A-D121-4F61-96B7-A1F7407D69B1Q38933093-F58E8500-E090-4A81-83E7-B960CBE5E098Q38961595-48586686-67D2-4BEB-A131-9420DD876DABQ42360527-480961DA-97CE-4272-AB91-6268EBFC2EEBQ45946417-97126747-2BD7-4A17-859F-DAA86AC38AD9Q46433745-C4591366-3147-48D3-8A0B-40F4AC9562F4Q46673511-1DB4D464-C813-4B06-9BAA-D032150082CAQ47130142-E52C6153-F662-4FB8-B120-06EEFA9E94F9Q47849185-FF44ED3E-474A-4555-9BF5-9F40DC323017Q51102102-C01EB191-36C9-4666-8C00-071F93FA3B92Q53724801-512ED9C8-77D1-4F3D-A03F-5C44095A7F63Q55032443-8F333C70-DBC0-4C04-9ACF-830446622FF0
P2860
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
@en
type
label
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
@en
prefLabel
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
@en
P2093
P1433
P1476
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
@en
P2093
Huidong Yu
Mingyun Shen
Peichen Pan
P304
P356
10.1016/J.DRUDIS.2013.09.010
P577
2013-09-25T00:00:00Z